|curasan AG -- Germany Stock|| |
EUR 1.05 0.08 8.25%
Mr. Scott V. Ogilvie is Independent Director of Neuralstem Inc. Mr. Ogilvie is currently the President of AFIN International Inc. a private equitybusiness advisory firm which he founded in 2006. Additionally Mr. Ogilvie has served as a partner of Wirthlin Worldwide International a private strategic advisory and MA firm since September 2011. Prior to December 31 2009 he was CEO of Gulf Enterprises International Ltd a company that brings strategic partners expertise and investment capital to the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group Inc. an investment manager a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill Farrer Burrill and has extensive public and private corporate management and board experience in finance real estate and technology companies. During the past 5 years Mr. Ogilvie has served on the board of directors of Innovative Card Technologies Inc. Preferred Voice Inc GenSpera Inc. and Research Solutions Inc. .
Age: 60 Director Since 2008
49 6027 40 900 51 http://www.curasan.de
The company has return on total asset (ROA)
of (15.5) %
which means that it has lost $15.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (39.32) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 695 K in total debt with debt to equity ratio (D/E) of 10.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. curasan AG has Current Ratio of 1.18 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.
curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Healthcare Products classification in Germany and traded on Frankfurt Stock Exchange. It employs 36 people.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 36 people.